The most common mutations in metabolic enzymes in cancer are somatic mutations in the IDH1/2 genes which are found in >80% of low-grade glioma and ∼20 to ∼30% of acute myeloid leukemia (AML) patients (2, 3, 4). This evidence concerns the gene IDH1 and cancer.